Basic Information
REPAGLINIDE MEVON TABLETS 1 MG
TABLET
Regulatory Information
SIN16375P
November 12, 2021
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XA10BX02
Company Information
Active Ingredients
Strength: 1.0 mg
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Diabetes mellitus type 1, C-peptide negative - Diabetic ketoacidosis, with or without coma - Severe hepatic function disorder - Concomitant use of gemfibrozil (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.